A treatment mechanism promotes the survival of those with a kind of leukemia alive

A new study, published in the New England Magazine, showed a great improvement in the survival for adults diagnosed with some kind of acute lymphocytes, known as ‘bi -cells’. This type of quickly developed cancer, and is characterized by the presence of excess immature white blood cells, known as lymphoma- in the bone marrow and blood, which is a subtype of acute lymphocytes affecting adults. This result comes from the study of the third phase called E1910, which was evaluated by the use of immunotherapy with bibathinomab in patients who underwent the initial chemotherapy treatment. In a 3 -year follow -up, 85% of patients who received additional chemotherapy were in addition to the living, compared to 68% of those who received only chemotherapy. Blinomomab is an immune agent that targets CD19 antigens on the bacterial cells, which helps the immune system discover and destroy cancer cells. Using Planetomomab on June 14, 2024, the US Food and Drug Administration (FDA) agreed to use Planetomomaba in adults and sick children with acute lymphatic leukemia, and the study shows that the addition of Blainomomab to enlarged chemotherapy improves the survival of patients. The researchers believe this approach will be the new standard for patients for patients, and the study included 224 patients between 30 and 70 years, and the participants were randomly appointed to receive either four courses of chemotherapy alone, or a mixture of chemotherapy and bibinomumab. A new hope for cancer patients and patients in the experimental group received volatile courses from Blinomomab and Chemotherapy, and after medium follow -up of 43 months, the study found that the BlinomaBab group, in addition to chemotherapy, achieved a total survival rate of 85% for a period of three years, compared to 68% in the chemotherapy. In addition, the survival rate without a setback was 80% in the Blinomomab group, compared to 66% in the chemotherapy group, and although treatment was generally well tolerated, some patients suffered from serious side effects, especially nervous problems. However, these cases could be controlled in most cases, and there were 17 deaths in the Blinomomab group, mainly due to relapse or infection, compared to 40 deaths in the chemotherapy group. The study was held independently of the pharmaceutical industry, with general funding from the National Institute of Cancer, and the study provides new hope for patients suffering from this aggressive form of leukemia, making Plainomabab a decisive element in their treatment system.